Systematic Review
Run PRISMA-style biomedical literature reviews with PubMed and PMC search lanes, screening logic, evidence tables, certainty summaries, and durable review artifacts.
Protocol, screening decisions and evidence tables matter more than a polished narrative.
Write the protocol before searching.
Keep exclusions and contradictions visible.
Link each conclusion to included evidence.
A literature review becomes unreliable long before the prose is written. The decisive moments are the choice of question, the search boundary, the exclusion rule and the treatment of contradiction.
Define the population, intervention or exposure, comparator, outcomes, date range, languages and eligible study designs before retrieval. Record databases, queries and the planned synthesis. PRISMA 2020 provides a 27-item reporting framework and revised flow diagrams, while making clear that reporting quality is not the same as methodological quality (Page et al.). That distinction should remain visible.
ARiDA treats the protocol as part of the governed case. Search results are retained as records. Deduplication preserves provenance across copies. Screening decisions carry reasons, including every full-text exclusion. A later reviewer can distinguish “not found,” “found and excluded” and “included but judged weak.”
The evidence table should capture population, intervention, comparator, outcome definition, follow-up, effect estimate, uncertainty, study design, limitations and source. Those fields force unlike studies to remain unlike. A randomized trial and a retrospective cohort may inform the same question without deserving the same authority.
Contradictory results stay side by side. ARiDA’s evidence layer can track support, opposition, coverage and source authority without asking a language model to average them into consensus. The writer synthesizes the accepted table and points to the records behind each material claim.
A useful review ends by stating what the evidence can change. Does it alter target confidence, identify a safety veto, narrow a patient segment or justify an experiment? If the evidence is insufficient, name the missing study rather than filling the space with cautious prose.
The released article or brief is one view of the evidence set. The durable product is the protocol, record flow, inclusion logic and table that another scientist can reopen when the literature changes.
Next move
Continue through the blog for adjacent workflow playbooks and engineering essays, or return to the homepage to view the broader platform story and capability surface.
Related solutions
Run PRISMA-style biomedical literature reviews with PubMed and PMC search lanes, screening logic, evidence tables, certainty summaries, and durable review artifacts.
Keep reading
A useful landscape explains which competitor changes the target profile, timing or investment case.
Rank biology, clinical feasibility and economics while keeping hard gates and missing evidence separate.
Use hard gates, uncertainty and resource constraints to expose the real allocation choice.